Lidija Poposka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3611691/publications.pdf

Version: 2024-02-01

566801 580395 26,771 35 15 25 citations h-index g-index papers 37 37 37 20757 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile. Current Pharmaceutical Design, 2021, 27, 3221-3228.	0.9	11
3	Developing A Deep Learning Solution to Estimate Instantaneous Glucose Level from Heart Rate Variability. , 2021, , .		1
4	Sex-related differences regarding cephalic vein lead access for CIEDs implantation. International Journal of Arrhythmia, 2021, 22, .	0.3	0
5	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	1.0	647
6	Noninvasive Glucose Measurement Using Machine Learning and Neural Network Methods and Correlation with Heart Rate Variability. Journal of Sensors, 2020, 2020, 1-13.	0.6	48
7	Correlating Glucose Regulation with Lipid Profile. Communications in Computer and Information Science, 2020, , 217-227.	0.4	O
8	Coronavirus Disease-19 and Cardiovascular Disease. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 39-44.	0.1	2
9	Trends from Minimally Invasive to Non-invasive Glucose Measurements. , 2020, , .		4
10	Design of a Non-invasive ECG-based Glucose Measurement System. , 2020, , .		8
11	Heart Rate Variability of 30-minute ECG Measurements and Correlation to Glucose Levels. , 2020, , .		1
12	Correlating Short-Term Heart Rate Variability and Instantaneous Blood Glucose Measurements. , 2020, , .		5
13	Evaluation of User Satisfaction with the ECGalert System. , 2019, , .		2
14	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.	1.0	8
15	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). American Journal of Cardiology, 2018, 122, 578-583.	0.7	12
16	The Challenge of Thromboprophylaxis in Cancer Patientsâ€"Balancing the Thrombotic and Bleeding Risks. Thrombosis and Haemostasis, 2018, 118, 1347-1349.	1.8	4
17	Scoring System Assessment of Cephalic Vein Access for Device Implantation. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3284-3290.	0.2	2
18	Electrocardiographic Parameters as Predictors of Response to Cardiac Resynchronization Therapy. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 297-302.	0.1	5

#	Article	IF	CITATIONS
19	Secondary Thromboprophylaxis in Hereditary Thrombophilia. Cardiology and Angiology, 2018, 7, 1-9.	0.0	0
20	Applicability of the ECGalert solution., 2017,,.		1
21	2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTS. Russian Journal of Cardiology, 2017, , 7-86.	0.4	87
22	Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?. Anatolian Journal of Cardiology, 2017, 18, 77-79.	0.5	5
23	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
24	Anticoagulation Management in Patients with Pacemaker-Detected Atrial Fibrillation. Open Access Macedonian Journal of Medical Sciences, 2016, 4, 243-247.	0.1	1
25	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	1.0	2,176
26	Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. Chest, 2010, 137, 263-272.	0.4	5,657
27	Progression From Paroxysmal to Persistent Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 725-731.	1.2	579
28	A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest, 2010, 138, 1093-1100.	0.4	3,810
29	Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation. European Heart Journal, 2008, 29, 1181-1189.	1.0	247
30	Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. Journal of the American College of Cardiology, 2007, 49, 572-577.	1.2	370
31	Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. European Heart Journal, 2006, 27, 2969-2974.	1.0	150
32	Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. European Heart Journal, 2006, 27, 3018-3026.	1.0	353
33	Induction of atrioventricular node reentry by simultaneous anterograde conduction over the fast and slow pathways. Prilozi / Makedonska Akademija Na Naukite I Umetnostite, Oddelenie Za Bioloiki I Medicinski Nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences. 2006. 27, 113-20.	0.2	1
34	Atrial fibrillation management: a prospective survey in ESC Member Countries. European Heart Journal, 2005, 26, 2422-2434.	1.0	770
35	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890.	1.0	532